Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 27, 2009, Pages 3181-3186

  Gu, Yongchuan ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bioreductive prodrugs; LC MS MS; Metabolites; Nitrogen mustards; Pharmacokinetics; PR 104

Indexed keywords

ANALYTES; ANTI-CANCER AGENTS; BIOREDUCTIVE PRODRUGS; CLINICAL TRIAL; EXTRACTION RECOVERY; GLUCURONIDES; HUMAN PATIENTS; HUMAN PLASMAS; LC-MS/MS; LINEAR RANGE; NITROGEN MUSTARDS; PHARMACOKINETIC STUDIES; PLASMA PROTEIN; PR-104; PRODRUGS; RAPID RESOLUTION; RUNTIMES; TANDEM MASS SPECTROMETRY; ULTRA-HIGH-PRESSURE LIQUID CHROMATOGRAPHY; VALIDATED METHODS;

ACETONITRILE; AMINES; BIOMOLECULES; CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETERS; MASS SPECTROMETRY; METABOLISM; METABOLITES; METHANOL; NITROGEN COMPOUNDS; ORGANIC ACIDS; ORGANIC POLYMERS; PHARMACOKINETICS; PLASMA (HUMAN); PLASMAS;

HIGH PRESSURE LIQUID CHROMATOGRAPHY;

ANTINEOPLASTIC AGENT; DRUG METABOLITE; METHANOL; PR 104; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; NITROGEN MUSTARD COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME FACTORS;

BRASSICACEAE;

EID: 69749096838     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.08.009     Document Type: Article

References (18)

1. Brown J.M., and Giaccia A.J. Cancer Res. 58 (1998) 1408
2. Brown J.M., and Wilson W.R. Nat. Rev. Cancer 4 (2004) 437
3. Rauth A.M., Melo T., and Misra V. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 755
4. Stratford J., and Workman P. Anticancer Drug Des. 13 (1998) 519
5. Brown J.M. Cancer Res. 59 (1999) 5863
6. McKeown S.R., Cowen R.L., and Williams K.J. Clin. Oncol. 19 (2007) 427
7. Chen Y., and Hu L. Med. Res. Rev. 29 (2009) 29
8. Patterson A.V., Ferry D.M., Edmunds S.J., Gu Y., Singleton R.S., Patel K., Pullen S.M., Syddall S.P., Atwell G.J., Yang S., Denny W.A., and Wilson W.R. Clin. Cancer Res. 13 (2007) 3922
9. Singleton R.S., Guise C.P., Ferry D.M., Pullen S.M., Dorie M.J., Brown J.M., Patterson A.V., and Wilson W.R. Cancer Res. 69 (2009) 3884
10. Gu Y., Patterson A.V., Atwell G.J., Chernikova S.B., Brown J.M., Thompson L.H., and Wilson W.R. Mol. Cancer Ther. 8 (2009) 1714
11. Patel K., Lewiston D., Gu Y., Hicks K.O., and Wilson W.R. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 856 (2007) 302
12. Jameson M.B., Rischin D., Pegram M., Gutheil J., Patterson A.V., Wilson W., and Denny W. J. Clin. Oncol. Suppl. 18s (2007) abstract no. 3516
13. Guise C.P., Wang A., Thiel A., Bridewell D., Wilson W.R., and Patterson A.V. Biochem. Pharmacol. 74 (2007) 810
14. Patterson A.V., Guise C.P., Abbattista M., van Leeuwen W., Pullen S.M., Ferry D.M., Denny W.A., Guilford P., and Wilson W.R. EJC Suppl. 6 (2008) 473
15. W.A. Denny, G.J. Atwell, S. Yang, W.R. Wilson, A.V. Patterson, N.A. Helsby, PCT/NZ 2004/529249 (2005).
16. Atwell G.J., and Denny W.A. J. Labelled Comp. Radiopharm. 50 (2007) 7
17. Bland J.M., and Altman D.G. Lancet 1 (1986) 307
18. Helsby N.A., Wheeler S.J., Pruijn F.B., Palmer B.D., Yang S., Denny W.A., and Wilson W.R. Chem. Res. Toxicol. 16 (2003) 469